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Abstract The bone marrow constitutes an unique micro-
environment for cancer cells in three specific aspects. First,
the bone marrow actively recruits circulating tumor cells
where they find a sanctuary rich in growth factors and
cytokines that promote their proliferation and survival.
When in the bone marrow, tumor cells profoundly affect the
homeostasis of the bone and the balance between osteo-
genesis and osteolysis. As a consequence, growth and
survival factors normally sequestered into the bone matrix
are released, further fueling cancer progression. Second,
tumor cells actively recruit bone marrow-derived precursor
cells into their own microenvironment. When in the tumors,
these bone marrow-derived cells contribute to an inflam-
matory reaction and to the formation of the tumor
vasculature. Third, bone marrow-derived cells can home
in distant organs, where they form niches that attract
circulating tumor cells. Our understanding of the contribu-
tion of the bone marrow microenvironment to cancer
progression has therefore dramatically improved over the
last few years. The importance of this new knowledge
cannot be underestimated considering that the vast majority
of cancer treatments such as cytotoxic and myeloablative
chemotherapy, bone marrow transplantation and radiation
therapy inflict a trauma to the bone marrow microenviron-
ment. How such trauma affects the influence that the bone
marrow microenvironment exerts on cancer is still poorly
understood. In this article, the reciprocal relationship
between the bone marrow microenvironment and tumor
cells is reviewed, and its potential impact on cancer therapy
is discussed.
Keywords Tumormicroenvironment.Angiogenesis.
Vasculogenesis.Metastasis.Bonemarrow
microenvironment.Bonemarrowstemcells
Abbreviations
EC endothelial cells
BMDC bone marrow-derived cells
BMDSC bone marrow-derived stem cells
GFP green fluorescent protein
HSC hematopoietic stem cells
MSC mesenchymal stem cells
VEGF vascular endothelial cell growth factor
VEGFR VEGF receptor
CEC circulating EC
EPC endothelial progenitor cells
Cancer Microenvironment (2008) 1:23–35
DOI 10.1007/s12307-008-0010-7
C. F. Chantrain
Division of Hematology-Oncology, Department of Pediatrics,
Universite Catholique de Louvain,
Brussels, Belgium
C. F. Chantrain: E. Marbaix
Cell Biology Unit, Christian de Duve Institute of Cellular
Pathology, Universite Catholique de Louvain,
Brussels, Belgium
O. Feron
Unit of Pharmacology and Therapeutics,
Universite Catholique de Louvain,
Brussels, Belgium
E. Marbaix
Department of Pathology, School of Medicine,
Universite Catholique de Louvain,
Brussels, Belgium
Y. A. DeClerck (*)
Division of Hematology-Oncology, Departments of Pediatrics and
Biochemistry and Molecular Biology, University of Southern
California Keck School of Medicine and The Saban Research
Institute of Childrens Hospital Los Angeles,
4650 Sunset Boulevard, MS #54,
Los Angeles, CA, USA
e-mail: declerck@usc.eduG-CSF granulocyte colony stimulating factor
GM-CSF granulocyte-macrophage colony stimulating
factor
MMP matrix metalloproteinases
SDF-1 stromal derived factor-1
IL interleukin
TEM Ti-2 expressing monocytes
PPC pericyte progenitor cells
Introduction
In their seminal paper published in 2000, Hanahan and
Weinberg [1] identified six critical hallmarks of cancer that
together represent the fundamental mechanisms underlying
malignant transformation and cancer progression. In view
of the complexity of the mechanisms underlying each of
these hallmarks, it is not surprising that cancer remains the
leading cause of death in humans age 40 to 65 and a major
challenge for the scientific and medical community. There
is a fundamental difference among these hallmarks. Self
sufficiency in growth signals, the ability to evade apoptosis,
insensitivity to anti-growth signals and limitless replicative
potential are four among the six hallmarks that have their
basis on genetic and epigenetic changes in the genome of
the cancer cells. In contrast, sustained angiogenesis and the
capability to invade and metastasize, are two hallmarks that
have their basis not only on genetic and epigenetic
alterations but also on dramatic changes in normal cellular
and acellular elements that support malignant cells. These
non-malignant components of the tumor are known to form
the tumor microenvironment. For the last two decades, the
primary focus of investigations on the microenvironment
has been on the tissues that are directly adjacent to primary
and metastatic tumors. Connective tissue proteins, the
basement membrane, adjacent endothelial cells (EC), and
stromal fibroblasts have been the subject of numerous
investigations in tumor invasion and angiogenesis that have
led to the recent successful use of anti-angiogenic therapies
[2]. In this aspect, the mechanisms by which the bone
marrow and the bone, which are frequent sites of
metastasis, provide a unique microenvironment for the
proliferation and survival of metastatic tumor cells have
been well characterized [3, 4]. However, the fact that non-
malignant cells from distant organs, primarily the bone
marrow, can contribute to the microenvironment of primary
and metastatic tumors has received little attention in the
past but has now been increasingly appreciated. Tumors
actively recruit bone marrow-derived cells (BMDC) which
contribute to inflammation and vascularization in the tumor
microenvironment (Table 1). Central to the contribution of
the bone marrow to tumor progression are bone marrow-
derived stem cells (BMDSC). Evidence supporting a
contribution of these cells to tumor progression and distant
metastasis has now been clearly obtained from animal
experiments in which lethally irradiated recipient mice are
transplanted with donor bone marrow cells that express a
marker protein such as green fluorescent protein (GFP),
luciferase or LacZ.
The relationship between the bone marrow and tumor
cells is reciprocal. Tumor cells leave the primary tumor as
they intravasate into the blood circulation and are actively
recruited into the bone marrow microenvironment. When
homed to the bone marrow they disrupt the homeostatic
balance between osteogenesis and osteolysis and create a
microenvironment that favors their growth and survival [5].
And vice-versa, BMDC leave the bone marrow osteoblastic
niche to enter the blood circulation and colonize the
primary tumor where they contribute to the tumor vascu-
lature and to an inflammatory reaction that deeply affects
malignant transformation and progression [6, 7]. BMDC
can also colonize distant organs and form a pre-metastatic
niche that will attract circulating tumor cells and promote
the formation of macroscopic tumors [8]. In this article,
these aspects will be specifically discussed. The bone
marrow is also home to non-innate immunocompetent cells
(cytotoxic T cells, NK cells, antigen presenting cells and B
cells) that initiate and coordinate an immune attack against
cancer cells. The contribution of these cells to cancer
progression will however not be discussed in this article as
it is beyond its scope
Bone Marrow-Derived Stem Cells
Hematopoietic Stem Cells and Endothelial Progenitor Cells
Bone marrow-derived hematopoietic stem cells (HSC) are
developmentally related to endothelial progenitors and arise
during embryonic development from a common hemangio-
blast precursor cell [9]. Embryonic hemangioblasts are
phenotypically similar to adult HSC and express c-Kit
(CD117), Sca-1 and CD133, but not Lin [10]. These cells
have been shown to be a common precursor of both
hematopoietic and endothelial cells [10, 11]. As they cells
mature they express one of two forms of the vascular
endothelial cell growth factor receptor (VEGFR)-1 or -2 [7,
12]. HSC express VEGFR-1 as they proliferate, differenti-
ate, and migrate in the blood circulation. These cells, which
are CD45 positive, colonize the primary tumor where they
contribute to inflammation and to the perivascular space.
They also colonize distant organs where they contribute to
metastasis as will be discussed later. In contrast, cells
expressing VEGFR-2 differentiate into circulating endothe-
lial progenitor cells (CEP) and later mature EC that merge
24 C.F. Chantrain et al.with EC originating from adjacent blood vessels to form the
tumor vasculature [13, 14]. CEP in the peripheral blood,
which derive from hemangioblasts, are phenotypically
defined as negative for CD45 and positive for CD13/
aminopeptidase N, VEGFR-2, CD117/Kit and CD34 [15].
Since CD34 is also expressed on mature circulating EC
(CEC), the expression of the marker CD133 allows the
distinction between CEP which are negative for CD133 and
CEC that express CD133 [16]. However, some studies have
shown that HSC are not the only source of bone marrow
derived EC [17], suggesting therefore that endothelial
lineage probably derives from hemangioblasts and non-
hematopoietic stem cells in adults.
Mesenchymal Stem Cells
The second type of stem cells in the bone marrow is the
pool of mesenchymal stem cells (MSC) [18]. These cells do
not express the HSC marker CD34, but express multiple
other markers likeStro-1, CD105/endoglin,CD44/hyaluronic
receptor and CD90 [19, 20]. When cultured, they typically
adhere to plastic or ECM proteins, and can differentiate into
a large variety of mature mesenchymal cells including
osteoblasts/osteocytes, chondrocytes, cardiomyocytes, myo-
cytes, adipocytes and even neuronal cells [21, 22]. Their
pool in the bone marrow is enhanced by Wnt-3a, a member
of the Wnt family of growth factors. [23]. These cells are the
subject of a growing attention because of their potential
therapeutic value in wound repair and tissue regeneration.
Their contribution to tumor progression is less well
understood than HSC but they play an important role in
bone metastasis, as will be discussed later.
Bone Marrow Niches
The fate of BMDSC, in particular HSC, is controlled by the
microenvironment in the bone marrow. This microenviron-
ment is made of specific niches that provide support for the
proliferation and maintenance of stem cells [24]. Interac-
tions between stem cells and their microenvironment
regulate their maintenance, proliferation, differentiation
and migration into the blood circulation (Fig. 1). Distinct
niches have been anatomically and physiologically defined
within the bone marrow [25, 26]. In the endosteal region,
osteoblasts and other mesenchymal-derived stromal cells
such as reticular cells, fibroblasts and adipocytes constitute
the osteoblastic niche that supports the maintenance of
HSC in a quiescent and undifferentiated state. Alteration
of normal osteoblastic function results in a decrease of
hematopoiesis and vice versa expansion of osteoblasts is
associated with an increased number of HSC in the bone
marrow [27, 28]. In the central region of the bone marrow,
EC in sinusoids contribute to the formation of a second
compartment defined as the vascular niche. BMDSC are
recruited in this niche where they proliferate, differentiate
and migrate through the sinusoidal wall [26]. Thus whereas
the osteoblastic niche promotes the maintenance of a pool
of undifferentiated stem cells, the vascular niche promotes
the release of differentiated and mature hematopoietic cells.
The mechanisms by which the microenvironment of the
niche interacts with stem cells and controls their fate
include adhesion and humoral factors [29]. Among these
is the angiopoietin-1/Tie-2 axis. HSC express the receptor
tyrosine kinase Tie2 and adhere to osteoblasts that express
angiopoietin-1 in the bone marrow niche. The interaction of
Table 1 Bone marrow-derived precursor cells and their role in tumor progression
Cell Phenotype Progeny Function
Hemangioblast CD133
+, CD105
+, CD31
+ HSC and endothelial
progenitors
HSC CD34
+, Kit
+, Sca1
+, CD31
− Hematopoietic precursor:
lymphocytes, platelets,
myeloid and endothelial
Give rise to VEGFR-1 and VEGFR-2 + cells
VEGFR-1 positive VEGFR-1
+, CD45
+, Sca-1
+ Myelo-monocytic cells,
mast cells, neutrophils
Inflammation in primary tumor and
premetastatic niche
VEGFR-2 positive VEGFR-2
+, CD31
+ Endothelial cells Neo-angiogenesis
MSC CD34
−, CD105
+, CD44
+, Stro-1
+ Mesenchymal precursors,
cytokine production,
osteoclast activation.
Osteoclast activation in bone marrow,
pericytes in tumor vessels, promote distant
metastasis when recruited in primary tumor
EPC CD45
−,C D 1 3
+, CD117 (Kit)
+,V E G F R - 2
+,
VEGFR-1
−,C D 1 3 3
−,C D 3 4
+
Endothelial cells Neo-angiogenesis
CEC CD45
−,C D 1 3
+, CD117 (Kit)-, VEGFR-2
+,
VEGFR-1
+,C D 1 3 3
+,C D 3 4
+
Circulating mature
endothelial cells
Shed from mature vasculature
PPC PDGFRβ
+, Sca-1
+, CD11b
+
or CD45
+/CD11b
+
Pericytes Become NG2 pos.(α-SMA and desmin pos.
or neg.) mural cells in new blood vessels
TEM Tie-2
+, CD13
+, Sca1
+ Monocytes Become NG2 pos. (Tie-2 neg.) pericytes
Bone marrow and tumor progression 25Tie-2 with its ligand angiopoietin-1 maintains in vivo the
long-term repopulating activity of HSC. Angiopoietin-1
promotes in HSC a state of quiescence and their adhesion to
the bone, protecting the HSC compartment from myelo-
suppressive stress [30]. Adhesion of HSC to osteopontin
present in endosteal bone via β1 integrin, is another
adhesion mechanism that promotes the maintenance of
HSC in the endosteal niche [31]. Among the humoral
factors that control the fate of HSC is the chemokine,
stromal-derived factor-1 (SDF-1), also called CXCL12.
SDF-1 is produced by bone marrow stromal cells and
osteoblasts, and binds to its receptor CXCR-4 expressed at
the cell surface of BMDSC. It thus acts as a retention factor,
promoting the maintenance of BMDSC in the osteoblastic
niche [32]. The balance between the osteoblastic and the
vascular niche as well as the mobilization of BMDSC to
the peripheral circulation is a dynamic process that can be
altered by various traumatic conditions such as chemother-
apy, radiation therapy, bone marrow transplantation, hyp-
oxia, or tumor invasion. This balance is modulated by
multiple cytokines, chemokines, proteolytic enzymes and
adhesion molecules [33]. Among the proteases involved,
matrix metalloproteinase-9 (MMP-9) should be discussed
in particular. MMP-9 is expressed by stromal cells and
HSC in the bone marrow and its production is increased
upon treatment with cytotoxic drugs like 5 fluorouracil
(5FU) that also stimulates the release of BMDSC from the
osteoblastic niche toward the vascular niche. MMP-9 exerts
its proteolytic activity on several specific proteins that
control the proliferation and fate of HSC in the bone
marrow. First, it cleaves membrane-associated Kit-Ligand
(mKit-L) expressed by stromal cells in the osteoblastic
niche. As a result, a soluble form of Kit-L (sKit-L) is
released which promotes the proliferation of HSC [34].
Second, MMP-9 degrades anchorage proteins such as
osteopontin, enabling the migration of HSC from the
osteoblastic to the vascular niche [35, 36]. Third, MMP-9
cleaves SDF-1 at a Ser
4–Lys
5 peptide bond that inactivates
the protein [37]. SDF-1 itself enhances the expression of
MMP-9 by BMDSC, thus promoting its own degradation
[38]. The HSC mobilizing agent, granulocyte-colony
stimulating factor (G-CSF), promotes HSC migration from
the osteoblastic niche toward the vascular niche in a similar
way by inducing neutrophil elastase degradation of SDF-1
[39]. By proteolytically degrading type IV collagen present
in the basement membrane. MMP-9 also promotes the
intravasation of BMSC into blood vessels. Thus, low levels
of MMP-9 result in high levels of mKit-L, poor release of
sKit-L and high levels of SDF-1 that retain HSC in the
osteoblastic niche. In contrast, high levels of MMP-9 result
in abundant release of sKit-L, inactivation of SDF-1 and
migration of HSC toward the vascular niche and HSC
differentiation [40] and intravasation into the peripheral
blood circulation. This therefore explains the higher
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Fig. 1 VEGFR-1 and 2 positive
precursor cells are released from
the bone marrow. HSC are
retained in the endosteal niche
by a combination of cell–cell
(Tie-2/angio-1), cell-matrix
(α4β1/osteopontin) and
receptor–ligand (CXCR-4/SDF-
1) interactions. The mobilization
of these cells toward the vascu-
lar niche and their release in the
peripheral blood is in part con-
trolled by MMP-9 which (1)
degrades SDF-1, (2) degrades
osteopontin, (3) solubilizes cKit-
L and (4) degrades the basement
membrane
26 C.F. Chantrain et al.mortality and impaired bone marrow recovery observed in
MMP-9 deficient mice post chemotherapy with 5FU [34].
Tumors Recruit Bone Marrow Derived Cells
which Contribute to Carcinogenesis and Progression
BMD-HSC Contribute to Inflammation in the Primary Tumor
Tumors recruit inflammatory cells into their stroma though
the expression of chemokines (Fig. 2). Most tumor cells
produce chemokines of the two major groups CXC and CC.
Typically, CXC chemokines are active on neutrophils and
lymphocytes whereas CC chemokines target monocytes,
eosinophils, dendritic cells, lymphocytes and NK cells [41].
Tumor cells and stromal cells also produce many other
growth factors such as VEGF, placental derived growth
factor (PlGF), a ligand that binds exclusively to VEGFR-1,
transforming growth factor-β (TGFβ) and macrophage
colony stimulating factor (M-CSF) that contribute to the
recruitment of monocytes and macrophages and the pro-
motion of their survival and differentiation into the tumor
[42, 43].
These inflammatory cells derive from VEGFR-1 positive
HSC [44][6, 45]. Although it was originally considered that
these cells incarnate the immune defense against develop-
ing tumors, there is accumulating evidence suggesting that
whereas full activation of adaptive immune cells at the
stage of tumor growth may result in eradication of
malignant cells, chronic activation of innate immune cells
at sites of premalignant growth may actually enhance tumor
development [46]. Bone marrow-derived inflammatory
cells contribute indeed to the transformation and prolifer-
ation of tumor cells, to the modulation of the immune
response and to the development of tumor vascularization,
and this process requires B lymphocytes [47].
Chronic inflammation has long been known as a
predisposing factor in various human cancers such as
breast, liver, colon, bladder, prostate, stomach, ovary and
skin carcinoma [6, 41]. In addition to potentially mutagenic
infectious agents that sustain chronic inflammation, inflam-
matory cells create a microenvironment favorable for the
transformation of normal proliferating cells. Inflammatory
cells, in particular phagocytic cells, generate reactive
oxygen and nitrogen species that contribute to the forma-
tion of the mutagenic agent peroxynitrite [48, 49]. Macro-
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Fig. 2 The primary tumor actively recruits BMDC. Tumor cells
release SDF-1, VEGF, PlGF, M-CSF and other cytokines that attract
HSC and MSC from the bone marrow. In the tumor tissue, VEGFR-1
pos. cells give rise to CD45 pos. myelo-monocytic cells, macrophages
and mast cells that contribute to an inflammatory reaction and to the
formation of the perivasculature. By producing MMP-9 these cells
further contribute to the solubilization of VEGF and other growth
factors. VEGFR-2 pos. cells give rise to endothelial cells and
contribute to the formation of a de novo vasculature. MSC are
recruited by primary tumors and give rise to pericytes and contribute to
the formation of distant metastasis by expressing CCL-5/RANTES that
stimulates tumor cell migration
Bone marrow and tumor progression 27phages express macrophage migration inhibitory factor
(MIF), a potent cytokine that bypasses p53 regulatory
functions and thus enhances the occurrence of oncogenic
mutations [50]. Inflammatory cells also contribute to tumor
cell proliferation by releasing growth factors like epidermal
growth factor (EGF), and cytokines like interleukin-6 (IL-6)
or tumor necrosis factor (TNF), as well as chemokines
such as SDF-1 that enhance leukocyte recruitment [45].
Tumor associated macrophages express immunosuppressive
molecules such as IL-10 and prostaglandin E-2 (PGE-2) that
allow tumor cells to evade the immune system [45]. Macro-
phages also contribute to tumor progression by assisting
tumor cells in intravasating [51, 52]. Mast cells contribute to
the early stages of tumorigenesis by stimulating proliferation
and malignant conversion but at the same time promoting a
more differentiated and less aggressive phenotype [53, 54].
Mice deficient in mast cells are also less sensitive to the
development of intestinal tumors when exposed to the
carcinogen 1,2-dimethylhydrazine [54] and exhibit a de-
creased rate of tumor angiogenesis [55]. A similar function
for tumor infiltrating neutrophils has been reported in another
model of multistage carcinogenesis [56]. Through the ex-
pression of MMP-9, mast cells, macrophages and neutrophils
play a critical role for the initiation of an angiogenic switch
that supports the growth of transformed cells into tumors
[57].
BMD-MSC Contribute to Metastasis
Bone marrow-derived mesenchymal stem cells (BMD-
MSC) have also been recently shown to be recruited in
large numbers in the stroma of developing tumors.
Although the role of these cells in tumor progression is
not fully understood, it has been recently suggested that
they may promote metastasis in a breast carcinoma model.
Dr. Weinberg’s laboratory has shown for example that
tumor cells stimulate the expression of chemokine CCL5
(RANTES) in mesenchymal stem cells, which then acts in a
paracrine manner to enhance tumor cell motility, invasion
and the formation of distant metastasis [58].
BMDC Contribute to Tumor Vascularization
Both VEGFR-1 and VEGFR-2 BMDC participate in the
development of tumor vascularization. Bone marrow-
derived inflammatory VEGFR-1 positive cells are recruited
to neo-angiogenic niches and support new blood vessel
formation [59]. Among these cells, macrophages infiltrate
hypoxic tumor areas and cooperate with tumor cells to
promote angiogenesis. Hypoxia enhances the expression
of several proangiogenic molecules by inducing the ex-
pression of the transcription factor hypoxia-inducible
factors (HIF) in macrophages. As a result, inflammatory
cells produce TGFβ, VEGF, PDGF, basic fibroblast
growth factor (bFGF) and specific chemokines that
stimulate tumor vascularization. These angiogenic chemo-
kines include CXCL1 through CXCL8 with the exception
of CXCL4 [45]. Several contain a Glu–Leu–Arg motif
(ELR motif) at the NH2-terminus, and stimulate EC
proliferation and chemotaxis by interacting with their
receptor CXCR-2. The contribution of ELR-containing
chemokines to tumor angiogenesis has been reported in
various human cancers [60]. SDF-1 which is produced by
tumor cells, macrophages and many stromal cells also
promotes tumor angiogenesis by recruiting CXCR-4
positive BMDC and VEGF and bFGF induce CXCR-4
expression in EC [61, 62]. Proteases produced by
VEGFR-1 HSC, and in particular MMP-9, play a critical
regulatory role in tumor angiogenesis. MMP-9 produced
by macrophages and mast cells releases ECM-bound
VEGF, and therefore increases its bioavailability and
biological activity [56, 63, 64]. MMP-9 also stimulates
the recruitment of pericytes along EC [65, 66]. Experi-
ments in many laboratories have shown that in mice either
genetically lacking MMP-9, treated with an inhibitor of
MMP or depleted in neutrophils, tumor development is
characterized by reduced frequency, decreased tumor
growth and reduced tumor vascularization [53, 56, 63–
66]. Occasionally, VEGFR-1 positive monocytes and imma-
ture myeloid cells acquire an EC-like phenotype and can be
identified in the tumor vascular endothelium [67, 68].
VEGFR-2 positive BMDC are also recruited into the
tumor and contribute to the endothelium and the formation
of a mature vascular network, a process called vasculo-
genesis or neo-angiogenesis [15, 59, 69, 70]. The level of
contribution of vasculogenesis to tumor vascularization is
however highly variable and depends on the tumor type, the
organ site, the development stage and the mouse strain in
animal models. Whereas in murine bone marrow transplan-
tation models the precise quantification of these cells is
possible using specific markers like EGFP, the quantifica-
tion of these cells in human tumors is hampered by
difficulties of marking and tracking BMDC [59]. As a
result, reports on the percentage of these cells in tumors
have been highly variable [71]. The bone marrow is also a
reservoir of pericyte progenitor cells (PPC) [72]. Two
subsets of PPC have been reported to be released by the
bone marrow, platelet derived growth factor receptor β
(PDGFRβ) positive, Sca-1
+ and CD11b
+ cells and CD45
+,
CD11b
+ cells [73]. Although they express Sca-1, whether
PDGFRβ
+ cells originate from HSC or MSC in the marrow
is unclear. Rajentie et al. [74] reported that a subpopulation
of BMDC expressing the NG2 pericyte-specific proteogly-
can, and the hematopoietic markers CD45 and CD11b
could be detected in the perivascular space of tumors where
they contribute to mural cells.
28 C.F. Chantrain et al.Finally, a few other BMDC that express neither VEFGR-
1 or VEGFR-2 can contribute to tumor vascularization.
Tie2 expressing CD13
+ monocytes (TEM) identified in
several mouse tumor models are recruited to tumor sites
and promote angiogenesis in a paracrine manner after
surrounding angiogenic tumor vessels. TEM home to peri-
endothelial sites similar to pericytes, and can differentiate
into α-SMA
+ pericytes which then become negative for
Tie-2 [75]. Precursors of dendritic cells (DC) termed
“vascular leukocytes” because they express VE-cadherin
in addition to CD45, CD11c, and MHC-II, also participate
in tumor vasculogenesis. These cells migrate toward tumor
vessels and contribute to the assembly of the tumor
neovasculature [76].
Contribution of BMDC to Cancer Metastasis
The Bone Marrow Attracts Tumor Cells
In many cancer types, circulating tumor cells can be easily
identified in the peripheral blood. Although the presence of
these cells is often a predictor of poor clinical outcome, it
does not necessarily mean that metastatic disease is present
or will occur [77, 78]. However these cells can be actively
recruited by the bone marrow. The mechanism by which the
bone marrow recruits these circulating tumor cells in its
microenvironment has been extensively studied (Fig. 3).
Central to this process is the production of chemokines by
bone marrow stromal cells that act as chemoattractants for
tumor cells. Among those, SDF-1 seems again to play the
major role. Many tumor cells express the SDF-1 receptor
CXCR-4 and thus, like HSC precursor cells, will be attracted
into the osteoblastic niche [79–82]. Animal experiments
have demonstrated that the migration of CXCR-4 positive
breast cancer cells toward the bone marrow can be blocked
when cells are pretreated with the CXCR-4 inhibitor AMD
3100 or a blocking antibody against CXCR-4. Down-
regulation of CXCR-4 in breast cancer cells also inhibits
their ability to colonize the bone, and CXCR-4 over-
expressing tumor cells have a higher propensity to form
bone marrow metastasis when injected intravenously in
mice [83, 84]. SDF-1 is however not the only chemokine
involved and other chemokines like the ELR-containing
CXCL10 have been shown to attract tumor cells in the bone
marrow [85]. When tumor cells reach the osteoblastic
niche, they do not remain quiescent like HSC and
significantly affect the homeostasis of the bone.
Tumor Cells Affect the Bone Microenvironment
The bone is a tissue primarily composed of type I collagen
and minerals in the form of hydroxyapatite that is normally
highly resistant to degradation. Under physiological con-
ditions, it is nevertheless one of the most active tissues
undergoing constant remodeling through a delicate balance
of new bone formation by osteoblasts and bone degradation
by osteoclasts. Osteoblasts are cells of mesenchymal origin
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Fig. 3 Tumor cells are recruited by the bone marrow where they alter
the osteoblasts and osteoclast balance. SDF-1, which is abundantly
present in the bone marrow, attracts CXCR-4 expressing tumor cells.
When in the bone marrow tumor cells interact with osteoblasts and
osteoclast precursor cells through the production of PTHrP, RANKL
and other osteoclast activating factors. Alternatively, tumor cells
stimulate MSC to make IL-6. As a result, osteoclasts are activated.
Tumor cells also inhibit osteoblast activity and new bone formation by
blocking the Wnt pathway via the production of Dkk1. This leads to
an increase in bone degradation and release of growth factors
Bone marrow and tumor progression 29that reside in the endosteal niche at the inner surface of the
bone where they interact with hematopoietic progenitor
cells [86]. Osteoclasts are cells derived from hematopoietic
progenitor cells of the monocyte-macrophage lineage and
are highly specialized and equipped to degrade the bone
matrix upon activation. Under pathological conditions like
osteoarthritis, osteoporosis or cancer metastasis, the remod-
eling of the bone is significantly increased and the balance
disrupted [81]. The presence of tumor cells in the
osteoblastic niche can shift bone remodeling toward an
excess in bone degradation, which will create osteolytic
bone metastases typically seen in breast cancer, multiple
myeloma, thyroid cancer and neuroblastoma or toward an
excess in bone synthesis and the formation of osteoblastic
metastases typically observed in prostate cancer. In most
cancer metastases, however, there is not pure osteolysis or
osteogenesis but a combination of both processes [3, 4].
The disruption of bone remodeling seen in cancer metas-
tasis is the result of a combination of humoral and adhesive
interactions between tumor cells and stromal cells in the
bone marrow microenvironment. A typical mechanism seen
in breast cancer bone metastasis involves the secretion of
parathyroid hormone-related peptide (PTHrP) by tumor
cells [87]. In response to PTHrP, osteoblasts express the
membrane bound receptor activator of NFkB ligand
(RANKL), a member of the TNF-α family of cytokines
and a key regulator of osteoclastogenesis [88]. RANKL
binds to its receptor RANK, present at the cell surface of
osteoclast precursor cells, and via NFkB activation stim-
ulates the transcriptional expression of genes like integrin
αvβ3, cathepsin K, MMP-9 and H
+-ATPase necessary for
osteoclast adhesion to the bone, the formation of an
osteolytic lacuna and bone degradation [89]. The interac-
tion between RANK and RANKL is regulated by osteo-
protegerin (OPG), a member of the TNF receptor family
produced by osteoblasts and bone marrow stromal cells that
acts as a decoy receptor for RANKL, preventing its
interaction with osteoclast-associated RANK [90]. This
interaction leads to inhibition of osteoclast differentiation,
maturation and activation. The degradation of the bone
matrix by osteoclasts has another important consequence on
the bone microenvironment that fuels the proliferation of
tumor cells. Many growth factors that are immobilized in
the bone matrix like TGF-β, IGF-I and II, PDGF, and bone
morphogenic proteins (BMP) are released in a soluble form
when the bone is degraded. These factors stimulate the
proliferation of osteoblasts but also of tumor cells, creating
a vicious circle [4]. Tumor cells can also directly activate
osteoclasts without interacting with osteoblasts by secreting
a variety of osteoclast activating factors (OAF) like IL-1,
IL-6, MIP1-α, M-CSF or RANKL which will stimulate
bone degradation. In other situations, tumor cells do not
produce OAF but will stimulate the expression of OAF by
MSC [91, 92]. This is, for example, the case in neuroblas-
toma and myeloma. Our laboratory has shown that in
neuroblastoma, tumor cells do not make OAF but stimulate
through a soluble factor, the expression of IL-6 by MSC,
which then acts as a potent activator of osteoclasts [93].
Neuroblastoma cells express the IL-6 receptor and thus
respond to IL-6 produced by MSC. The production of IL-6
by MSC not only stimulates osteoclasts but provides tumor
cells with a growth and survival advantage. For example we
have shown that neuroblastoma cells proliferate faster and
are resistant to drug-induced apoptosis when cultured in the
presence of MSC [94]. In myeloma, contact between
myeloma cells and bone marrow stromal cells also
stimulates the production of IL-6 by MSC and stromal
cells [95]. Tumor cells not only stimulate osteoclasts but
can also inhibit osteoblasts and osteogenesis. Osteoblast
activation and maturation is stimulated by the Wnt pathway
[96]. This pathway is negatively regulated by Dickkopf-1
(Dkk1), a soluble protein that when binding to Kremen and
LRP-5/6, two membrane associated receptors, prevents the
interaction of Frizzled-bound Wnt with LRP5/6 that is
required for activation of the canonical Wnt pathway [97].
Breast cancer cells and myeloma cells express Dkk1 and
expression of Dkk1 in these cells promotes osteolytic
metastasis by inhibiting bone synthesis [98–100]. In other
cases, tumor cells will promote osteoblast proliferation and
activity. This is in particular the case of prostate cancer cells
that express members of the bone morphogenic protein
family that stimulate osteoblasts and osteogenesis [101].
Thus tumor cells that have been recruited into the bone
marrow can dramatically modify the bone microenviron-
ment into a fertile soil that provides them with a substantial
proliferative and survival advantage. This explains why
when a cancer has metastasized to the bone, it is generally
rapidly progressive and resistant to chemotherapy.
BMDC Contribute to the Establishment of Distant
Metastasis
Until recently, the accepted dogma in metastasis has been
that distant organs are first colonized by a sub-population of
tumor cells from the primary tumor and that inflammatory
cells and EC are then recruited at these sites, where they
contribute to angiogenesis and stimulate the proliferation of
tumor cells. Recent provocative data however have sug-
gested that the order of these events may well be reversed
and that inflammatory cells may be the first ones to reach
metastatic sites, forming pre-metastatic niches that attract
circulating tumor cells [102]. Using irradiated mice trans-
planted with EGFP-expressing bone marrow cells and
injected subcutaneously with B16 or Lewis Lung tumor
30 C.F. Chantrain et al.cells, Kaplan et al. demonstrated that VEGFR-1 positive
BMDC colonize the lung or liver at least a week before
tumor cells reach these sites. They also demonstrated that
tumor cells only establish metastasis at sites that are
precolonized by VEGFR-1
+ BMDC and that metastasis
could be inhibited by treating the mice with an anti-
VEGFR-1 antibody or by removal of VEGFR-1 positive
cells from the marrow. The deposition of fibronectin at
these pre-metastatic sites seems to be critical in attracting
the VEGFR-1 positive cells that express the fibronectin-
binding integrin α4β1 (VLA4). It is postulated (Fig. 4) that
these cells could then alter the microenvironment leading to
the release of chemokines attracting tumor cells like SDF-1.
Soon after implantation of tumor cells at these sites,
VEGFR-2
+ cells are recruited from the bone marrow to
promote neo-angiogenesis. Production of VEGF and PlGF
by metastatic tumor cells stimulates angiogenesis and the
recruitment of additional VEGFR-1
+ BMDC. In support of
the possibility of a similar mechanism in human cancer
metastasis, the presence of VEGFR-1 positive cells in
histological sections of human metastatic tumors has been
demonstrated. Altogether the data suggest that circulating
tumor cells need specific niches to establish themselves and
form successful metastatic tumors. The bone marrow
therefore not only is a source of local osteoblastic niches
that promote the establishment of bone metastases but also
of distant pre-metastatic niches that attract circulating tumor
cells in distant organs where they find a favorable soil for
metastasis [26, 103].
Conclusion
It is now evident that the bone marrow plays a very unique
microenvironmental role in carcinogenesis, tumorigenesis,
angiogenesis and metastasis. Most of the experimental
evidence discussed in this article suggests that it has a
positive—and thus undesirable—effect on cancer progres-
sion. A major mechanism by which the bone marrow
contributes to cancer progression is by the release of
VEGFR-1 and VEGFR-2 precursor cells that are a source
of mature inflammatory and vascular cells. The vast
majority of the treatments currently used in human cancer,
including high-dose cytotoxic and myeloablative chemo-
therapy, bone marrow transplantation and radiation therapy,
cause an injury to the bone marrow that is followed by a
phase of recovery. The effect of such injuries to the bone
marrow microenvironment and in particular to the release
of VEGFR-1 and -2 positive cells is so far poorly
understood, but there is evidence that it may promote the
release of these BMDC. For example, in animal models of
limb injury the revascularization of the limb is accelerated
if the mice receive low-dose irradiation, because irradiation
of the bone marrow promotes the colonization of the
osteoblasts osteoblasts
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Fig. 4 The bone marrow
releases VEGFR-1 and 2 pos.
precursor cells that promote the
development of distant metasta-
ses. VEGFR-1 BMDC cells can
colonize distant organs via ad-
hesion to fibronectin forming
pre-metastatic niches (1). These
cells release SDF-1 that attracts
CXCR-4 circulating tumor cells
(2). When established in these
pre-metastatic niches, tumor
cells secrete VEGF, PlGF and
other cytokines that attract
VEGFR-2 pos. BMDC that will
contribute to neo-angiogenesis (3)
Bone marrow and tumor progression 31injured limb by BMDC. Not surprisingly, this process is
dependent on MMP-9 which increases the solubilization
of Kit-L and the release of VEGF which both contribute
to revascularization of the limb [104]. In mice treated with
cyclophosphamide there is an increased release of EPC in
the peripheral blood between 1 and 3 weeks after the
administration of the cytotoxic agent. This release however
is only observed if a bolus maximal tolerable dose is
administered and not if low-dose metronomic doses are
given [105, 106]. This thus supports the concept that high
dose pulse chemotherapy may stimulate the release of EPC
and ultimately tumor revascularization. In patients with
cancer, studies have also shown an increase in EPC post
high-dose chemotherapy [107]. However whether there is
actually an increase in tumor vasculogenesis post adminis-
tration of high-dose chemotherapy in human cancer has
not been demonstrated yet. The data nevertheless suggest
that pulses of high-dose chemotherapy may have an
unanticipated and detrimental side effect by promoting the
release of VEGFR-1 and -2 BMDC from the bone marrow
osteoblastic niche into the peripheral blood circulation [108].
This may have several important and negative conse-
quences on patient survival as it may not only promote
inflammation and vasculogenesis in the primary tumor but
also the formation of pre-metastatic niches and thus
metastatic disease. Should this concept be correct, a better
understanding of the mechanisms involved in the release of
BMDC and how it is affected by injury to the bone marrow,
will allow the design of new therapeutic protocols that
could prevent the increased release of BMDC from the
bone marrow niche (Fig. 5). For example, adding drugs that
target VEGF, PlGF, SDF-1 or MMP-9 immediately after a
pulse of high dose chemotherapy may prevent the release of
VEGFR-1 and R2 positive cells from the bone marrow and
their recruitment by the primary tumor or by pre-metastatic
niches. A decrease in the levels of circulating EPC in
patients with elevated VEGF levels in the peripheral blood
(POEMS syndrome) treated with Bevasizumab (Avastin)
has been recently shown [109]. MMP inhibitors have failed
in clinical trials in the past but were tested in chronic
administration in patients with end stage disease and with
a reduction in the primary tumor as the therapeutic goal
[110]. However when used for a short period of time
between courses of intensive chemotherapy, they may be
effective without unacceptable toxicity. Alternatively, inter-
vening with SDF-1/CXCR-4 signaling with small inhibitors
like AMD 3100 [111] may have a similar effect by pre-
venting the colonization of the primary tumor by BMDC
released into the peripheral blood post high-dose chemo-
therapy. There is clearly a fertile ground for investigation in
this area that has the potential to significantly influence the
way we administer chemotherapy to patients with cancer.
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Fig. 5 Revisiting the administration of high dose chemotherapy. a
Recent observations suggest that there is an increase in the level of
EPC after pulse high dose chemotherapy. This increase may favor
tumor progression and the establishment of distant metastases if these
cells are recruited by the primary tumor and by pre-metastatic niches.
b The administration of agents blocking the recruitment of VEGFR-1
and 2 positive BMDC between courses of high dose chemotherapy
may prevent a stimulation of neo-angiogenesis and the formation of
pre-metastatic niche post chemotherapy
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